Status:
COMPLETED
CPAP Treatment and Postoperative Outcomes in Patients With Rheumatic Valvular Heart Disease
Lead Sponsor:
Nanjing Medical University
Conditions:
Rheumatic Valvular Heart Disease
Obstructive Sleep Apnea
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The prevalence of OSA (Obstructive sleep apnea，OSA) is 2%-4% in general population and 16%-47% in surgical-heart failure patients. Our previous study found that OSA was associated with the increasing ...
Detailed Description
Between December 1, 2017 and June 30 2019, 200 patients with chronic heart failure caused by rheumatic valvular heart disease waiting for heart valve replacement in Department of Cardiovascular Surger...
Eligibility Criteria
Inclusion
- Patients aged 18-75 years.
- Patients with rheumatic valvular heart disease.
- Patients combined with obstructive sleep apnea (apnea-hypopnea index \>=5/h).
- Received heart valve replacement surgery.
- The enrolled patients having received patients' informed consent.
Exclusion
- History of stroke or clinical signs of peripheral or central nervous system disorders.
- History of Chronic obstructive pulmonary disease or asthma.
- Enrolment in another clinical study.
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2020
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT03398733
Start Date
December 1 2017
End Date
January 31 2020
Last Update
February 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029